Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram.
BACKGROUND
Omega-3 fatty acid (O3FA) levels and dimensional personality measures have been associated with major depression and the course of depressive illness. We sought to study the utility of O3FA levels and dimensional personality measures as predictors of early improvement with escitalopram.


METHODS
Twenty-four participants were enrolled in an open-label trial of escitalopram 10 mg/d for 4 weeks. Baseline erythrocyte O3 levels and dimensional personality assessments were obtained.


RESULTS
Using a conservative, intention-to-treat analysis, baseline neuroticism (r = -0.57; P = .007), as measured by the Revised NEO Personality Inventory but not erythrocyte O3 levels, was correlated with improvements on escitalopram. A facet analysis of the neuroticism domain showed the relationship with antidepressant response to be focused on trait anxiety (r = -0.65; P = .002).


CONCLUSIONS
Anxiety may have important prognostic implications on subsequent response to selective serotonin reuptake inhibitors, such as escitalopram.
Fiedorowicz
Jess G
JG
Departments of Psychiatry and Epidemiology, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA. jess-fiedorowicz@uiowa.edu
Hale
Nancy
N
Spector
Arthur A
AA
Coryell
William H
WH
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000097:blood / Q000188:drug therapy / Q000523:psychology; D002605:Character; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004912:Erythrocytes / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D010555:Personality Inventory / Q000706:statistics & numerical data*; D011379:Prognosis; D011446:Prospective Studies; D011594:Psychometrics; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D015525:Fatty Acids, Omega-3; D015283:Citalopram